These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 29951728)

  • 21. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
    Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
    Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.
    Sacco A; Aujay M; Morgan B; Azab AK; Maiso P; Liu Y; Zhang Y; Azab F; Ngo HT; Issa GC; Quang P; Roccaro AM; Ghobrial IM
    Clin Cancer Res; 2011 Apr; 17(7):1753-64. PubMed ID: 21355079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.
    Demo SD; Kirk CJ; Aujay MA; Buchholz TJ; Dajee M; Ho MN; Jiang J; Laidig GJ; Lewis ER; Parlati F; Shenk KD; Smyth MS; Sun CM; Vallone MK; Woo TM; Molineaux CJ; Bennett MK
    Cancer Res; 2007 Jul; 67(13):6383-91. PubMed ID: 17616698
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The evaluation of the anti-cancer activity of ixazomib on Caco2 colon solid tumor cells, comparison with bortezomib.
    Engür S; Dikmen M
    Acta Clin Belg; 2017 Dec; 72(6):391-398. PubMed ID: 28327055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.
    Arastu-Kapur S; Anderl JL; Kraus M; Parlati F; Shenk KD; Lee SJ; Muchamuel T; Bennett MK; Driessen C; Ball AJ; Kirk CJ
    Clin Cancer Res; 2011 May; 17(9):2734-43. PubMed ID: 21364033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs).
    Kuhn DJ; Orlowski RZ; Bjorklund CC
    Curr Cancer Drug Targets; 2011 Mar; 11(3):285-95. PubMed ID: 21247387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of proteasome inhibitors for treatment of multiple myeloma.
    Schlafer D; Shah KS; Panjic EH; Lonial S
    Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Myocyte-Damaging Effects of the BCR-ABL1-Targeted Tyrosine Kinase Inhibitors Increase with Potency and Decrease with Specificity.
    Hasinoff BB; Patel D; Wu X
    Cardiovasc Toxicol; 2017 Jul; 17(3):297-306. PubMed ID: 27696211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis.
    Verbrugge SE; Assaraf YG; Dijkmans BA; Scheffer GL; Al M; den Uyl D; Oerlemans R; Chan ET; Kirk CJ; Peters GJ; van der Heijden JW; de Gruijl TD; Scheper RJ; Jansen G
    J Pharmacol Exp Ther; 2012 Apr; 341(1):174-82. PubMed ID: 22235146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New orally active proteasome inhibitors in multiple myeloma.
    Allegra A; Alonci A; Gerace D; Russo S; Innao V; Calabrò L; Musolino C
    Leuk Res; 2014 Jan; 38(1):1-9. PubMed ID: 24239172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.
    Lee MJ; Bhattarai D; Yoo J; Miller Z; Park JE; Lee S; Lee W; Driscoll JJ; Kim KB
    J Med Chem; 2019 May; 62(9):4444-4455. PubMed ID: 30964987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proteasome Inhibitor Drugs.
    Fricker LD
    Annu Rev Pharmacol Toxicol; 2020 Jan; 60():457-476. PubMed ID: 31479618
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.
    Mitsiades CS
    J Clin Oncol; 2015 Mar; 33(7):782-5. PubMed ID: 25605842
    [No Abstract]   [Full Text] [Related]  

  • 34. The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.
    Richardson PG; Moreau P; Laubach JP; Gupta N; Hui AM; Anderson KC; San Miguel JF; Kumar S
    Future Oncol; 2015; 11(8):1153-68. PubMed ID: 25832873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Proteasome inhibitor].
    Yagi H
    Nihon Rinsho; 2014 Jun; 72(6):1125-9. PubMed ID: 25016815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteasome inhibitors: structure and function.
    Nunes AT; Annunziata CM
    Semin Oncol; 2017 Dec; 44(6):377-380. PubMed ID: 29935898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE.
    Seavey MM; Lu LD; Stump KL; Wallace NH; Ruggeri BA
    Int Immunopharmacol; 2012 Jan; 12(1):257-70. PubMed ID: 22178195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitors.
    Kloss A; Meiners S; Ludwig A; Dahlmann B
    Cardiovasc Res; 2010 Jan; 85(2):367-75. PubMed ID: 19564153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma.
    Kegyes D; Gulei D; Drula R; Cenariu D; Tigu B; Dima D; Tanase A; Badelita S; Buzoianu AD; Ciurea S; Ghiaur G; Terpos E; Ciechanover A; Einsele H; Tomuleasa C
    Blood Rev; 2023 Sep; 61():101100. PubMed ID: 37291017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors.
    Downey-Kopyscinski S; Daily EW; Gautier M; Bhatt A; Florea BI; Mitsiades CS; Richardson PG; Driessen C; Overkleeft HS; Kisselev AF
    Blood Adv; 2018 Oct; 2(19):2443-2451. PubMed ID: 30266819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.